Welcome to our dedicated page for Establishment Labs Hldgs SEC filings (Ticker: ESTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Establishment Labs Holdings Inc. (NASDAQ: ESTA) provides access to the company’s U.S. regulatory disclosures as a global medical device issuer focused on breast aesthetics and reconstruction. Through these documents, investors can review how Establishment Labs reports its financial condition, operating results, and key corporate agreements.
Core filings include annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company details revenue from its portfolio of breast health, breast aesthetics, and breast reconstruction products, as well as expenses, liquidity, and risk factors. These reports also describe its manufacturing operations in Costa Rica, quality system compliance under ISO 13485:2016 and FDA 21 CFR 820, and its intellectual property position, including patent applications and clinical evidence supporting its devices.
Current reports on Form 8-K are particularly relevant for tracking material events at Establishment Labs. Recent 8-K filings have covered earnings announcements for specific quarters and an amendment to the company’s credit agreement with Oaktree Fund Administration, LLC, including the availability of additional term loan tranches and related liquidity requirements. Such filings help clarify changes in capital structure, borrowing capacity, and other significant developments.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that explain the content of complex filings. Users can quickly understand the implications of new 10-K and 10-Q reports, 8-K current events, and other submissions without reading every page. The platform also surfaces insider transaction disclosures on Form 4, allowing users to monitor equity transactions by Establishment Labs’ directors and officers as reported to the SEC.
ESTABLISHMENT LABS HOLDINGS INC. director Juan Jose Chacon Quiros reported open-market sales totaling 75,000 Common Shares, executed indirectly through Sariel Group Ltd, an entity in which he has a pecuniary interest and over whose shares he has voting and dispositive power.
The sales occurred on May 1 and May 4, 2026 at weighted average prices between about $70 and $71 per share, under a Rule 10b5-1 trading plan. Following these transactions, Sariel Group Ltd holds 1,032,604 Common Shares indirectly attributed to him, and he also holds 45,193 Common Shares directly.
Establishment Labs Holdings Inc. entered into an amended credit agreement with Oaktree-affiliated lenders providing term loans of up to $300,000,000. The facility includes a $265,000,000 Tranche E funded at closing and a Tranche F of up to $35,000,000 available upon mutual consent.
About $259,000,000 from Tranche E will repay all obligations under the prior credit agreement and related costs, with remaining proceeds for working capital and general corporate purposes. The term loans bear interest at 8.75% per annum with partial payment-in-kind options in the first year, mature on April 30, 2031, carry a 1% original issue discount and a 1% exit fee on repayments, and are subject to prepayment premiums in the first three years.
ESTABLISHMENT LABS HOLDINGS INC. director Juan Jose Chacon Quiros reported indirect open-market sales totaling 75,000 common shares over April 23–27. The trades, executed at prices in the mid‑$60s per share, were carried out under a disclosed Rule 10b5-1 trading plan.
The shares were sold by Sariel Group Ltd., over which Chacon Quiros has voting and dispositive power, while disclaiming beneficial ownership beyond his pecuniary interest. After these sales, indirect holdings stood at 1,107,504 common shares, and a separate direct position was 45,193 common shares as of April 23.
Establishment Labs Holdings Inc. director-related entity Sariel Group Ltd sold 37,500 Common Shares of ESTA on April 14, 2026 in an open‑market transaction at a weighted average price of $65.228 per share, within a range of $65.00 to $65.60, under a pre‑arranged Rule 10b5-1 trading plan.
Following the sale, Sariel Group Ltd held 1,182,504 Common Shares indirectly attributable to director Juan Jose Chacon Quiros, while he also held 45,193 Common Shares directly. He disclaims beneficial ownership of Sariel Group Ltd’s shares except to the extent of his pecuniary interest.
Establishment Labs Holdings Inc. will hold its 2026 annual shareholder meeting virtually on May 22, 2026 at 1:00 pm Eastern Time. Shareholders will vote on electing six directors to one-year terms ending in 2027, an advisory “say‑on‑pay” approval of named executive officer compensation, and ratification of CBIZ CPAs P.C. as independent auditor for 2026.
The company reports 2025 revenue of $211.1 million, up 27.2% from 2024, with net loss narrowing to $51.1 million from $84.6 million and year‑end cash of $75.6 million. New CEO Filippo “Peter” Caldini’s pay mix emphasizes stock options, restricted stock units and an annual bonus tied to financial and strategic goals, reflecting a performance‑based compensation design.
ESTABLISHMENT LABS HOLDINGS INC. director and Chief Executive Officer Filippo Caldini reported equity compensation awards. He received stock options for 24,879 common shares at an exercise price of $76.23 per share, expiring on February 18, 2036, and a separate grant of 14,266 common shares.
According to the grant terms, one-fourth of both the stock units and the option shares vest on February 18, 2027, with additional one-fourth portions vesting on each one-year anniversary after that date, as long as he continues as a service provider. Following the share grant, he directly holds 49,511 common shares.
ESTABLISHMENT LABS HOLDINGS INC. director Edward J. Schutter exercised a stock option to acquire additional equity in the company. He exercised options covering 36,780 common shares at an exercise price of $4.11 per share via a cash exercise. Following the transaction, he directly owns 175,382 common shares, and the exercised option position has been fully converted into stock. The option had a multi-year vesting schedule, with half the shares vesting in 2016 and the remainder vesting in equal annual installments thereafter.
ESTABLISHMENT LABS HOLDINGS INC. director Leslie Gillin received an equity grant of common shares as part of regular board compensation. She acquired 297 common shares on the transaction date instead of a quarterly cash retainer, with the share amount based on the $56.78 closing price.
The shares were issued under the company’s 2018 Equity Incentive Plan and increase her direct holdings to 16,044 common shares. This is a routine, compensation-related award rather than an open-market purchase or sale.
Slotkin Bryan reported acquisition or exercise transactions in this Form 4 filing.
Establishment Labs Holdings Inc. director Bryan Slotkin received an automatic grant of 286 common shares valued at $56.78 per share. These shares were taken in lieu of his quarterly cash retainer under the company’s Outside Director Compensation Policy and issued from the 2018 Equity Incentive Plan.
Following this award, Slotkin directly holds 30,256 common shares. This is a routine, compensation-related equity grant rather than an open‑market share purchase.
LEWIN NICHOLAS SHERIDAN reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Nicholas Sheridan Lewin received a grant of 440 common shares, elected in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy. The shares were issued under the 2018 Equity Incentive Plan at a value based on the closing price of $56.78 per share.
Following this compensation award, Lewin directly holds 1,077,315 common shares. An additional 19,090 common shares are held indirectly through his spouse, reflecting associated family holdings rather than an open-market trade.